FierceBiotech Radio with NEA's Carol Gallagher

New Enterprise Associates Partner Carol Gallagher

New Enterprise Associates Partner Carol Gallagher joins FierceBiotech Radio to talk about her journey from Big Pharma to small biotech and eventually to venture capital, along the way shedding light on just what VCs do all day.

Download the episode on iTunes or listen below--and be sure to subscribe. Let us know what you think by dropping a line to [email protected] And if you missed last week's interview with Michael Gilman, CEO of the Atlas Venture-seeded Padlock Therapeutics, you can find it here.

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.